ACM
AVDL

Altium Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Altium Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-419,131
Closed -$3.28M – 2
2025
Q1 		$3.28M Sell
419,131
-33,344
-7% -$279K 7.91% 5
2024
Q4 		$4.76M Sell
452,475
-157,525
-26% -$1.91M 1.35% 30
2024
Q3 		$8M Hold
610,000
– – 2.36% 14
2024
Q2 		$8.58M Buy
610,000
+56,943
+10% +$928K 3.5% 11
2024
Q1 		$9.34M Buy
+553,057
New +$8.24M 3.7% 8
2023
Q2 		– Sell
-500,000
Closed -$4.58M – 71
2023
Q1 		$4.58M Buy
+500,000
New +$4.11M 2.54% 9
2022
Q1 		– Sell
-440,589
Closed -$3.56M – 120
2021
Q4 		$3.56M Hold
440,589
– – 0.98% 39
2021
Q3 		$4.32M Hold
440,589
– – 1.13% 35
2021
Q2 		$2.96M Hold
440,589
– – 0.69% 60
2021
Q1 		$3.98M Sell
440,589
-25,000
-5% -$202K 1.11% 31
2020
Q4 		$3.11M Buy
+465,589
New +$2.91M 1.16% 35

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Altium Capital Management's AVDL Position: Q2 2025 in Review

Altium Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q2 2025, closing a stake of 419,131 shares — an estimated $3.28M sold.

Altium Capital Management first reported a position in AVDL in Q4 2020 and held it in 11 quarters. The position peaked at $9.34M in Q1 2024. 173 funds tracked by Wall St. Rank hold AVDL as of Q2 2025.

  • Altium Capital Management reported no remaining Avadel Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Altium Capital Management sold 419,131 Avadel Pharmaceuticals shares in Q2 2025, an estimated $3.28M.
  • Altium Capital Management first reported a position in Avadel Pharmaceuticals in Q4 2020 and held it in 11 quarters.
  • Altium Capital Management's Avadel Pharmaceuticals position peaked at $9.34M in Q1 2024.
  • 173 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2025.

Based on Altium Capital Management's 13F filing for Q2 2025.